What Are The Purported Benefits Of CJC-1295 – With DAC (10mg)?
CJC-1295 with DAC (10 mg) is a long-acting GHRH analog primarily studied as a research peptide for sustained stimulation of the growth hormone (GH) axis. It is commonly discussed in research settings as a modulator of the growth hormone axis due to its ability to increase endogenous GH and IGF-1 over an extended period.
Purported Benefits (Research-Focused, Not Established Clinical Outcomes)
- Increased GH and IGF-1 Levels: Single and repeated subcutaneous doses have been shown in early human studies to increase mean GH (roughly 2–10x) and IGF-1 (roughly 1.5–3x) for days to weeks. This mechanism underpins most of the purported benefits.
- Lean Mass and Recovery Support (Hypothesized): Because GH/IGF-1 are linked to anabolic signaling, CJC-1295 with DAC is often discussed in relation to lean muscle growth, strength, and exercise recovery. However, strongly controlled body-composition data are limited.
- Fat-Loss and Metabolic Support (Mechanism-Based): GH-related lipolysis is frequently cited as a possible pathway to improved fat metabolism and reduced adiposity (including visceral fat), but these claims are largely based on mechanisms and small-scale observations.
- Sleep and Vitality-Related Research Hypotheses (Anecdotal/Low-Evidence): Some clinics and review-style sources mention improvements in deep sleep, skin appearance, and general vitality as indirect effects of elevated GH. These claims are not yet supported by strong, controlled clinical trials.
Important Note: A 10 mg vial refers to the peptide content, not the amount for a single administration. It is typically a lyophilized research vial intended for reconstitution and multi-dose experimental use.
What Is The Chemical Makeup Of CJC-1295 – With DAC (10mg)?
CJC-1295 with DAC is a synthetic long-acting GHRH analog that binds albumin, significantly extending its half-life compared with native GHRH.
- Category: Muscle growth and performance peptides
- CAS Number: 863288-34-0
- Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
- Molecular Weight: 3648.4 g/mol
- Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Malimide-beta-Ala)-NH2
- Synonyms: CJC1295, CJC-1295 with DAC
The DAC (Drug Affinity Complex) portion allows the peptide to bind to circulating albumin, forming a peptide–albumin conjugate that slows breakdown and clearance. This is what gives CJC-1295 with DAC its long-acting profile, with a reported human half-life of 5.8–8.1 days in early studies.
What Does Scientific Research Say About CJC-1295 – With DAC (10mg)?
The strongest published evidence for CJC-1295 with DAC comes from early human pharmacokinetic/pharmacodynamic studies, showing that it can produce sustained increases in GH and IGF-1.
A key Phase I study in healthy adults reported:
- Dose-dependent increases in mean GH (about 2–10x) lasting 6 days or more after a single subcutaneous injection
- IGF-1 increases (about 1.5–3x) lasting 9–11 days
- Estimated terminal half-life of about 5.8–8.1 days
- With repeated dosing, IGF-1 remained above baseline for up to 28 days
- No serious adverse reactions in the short-term trial; common effects were mild injection-site reactions and temporary flushing
These findings support its role as a long-acting GHRH analog, but they do not establish long-term safety or clinical outcome benefits.
Clinical and Experimental Outcome Evidence (Limited)
- Human Outcome Data Are Sparse: Beyond Phase I PK/PD research, there is limited peer-reviewed human evidence linking CJC-1295 with DAC to hard outcomes such as muscle gain, fat loss, or performance improvement.
- Mechanistic/Animal Evidence Exists But Is Limited: Some white papers and secondary summaries discuss possible applications in muscle regeneration, metabolic regulation, and repair pathways, but robust independently published animal datasets specific to CJC-1295-DAC are relatively limited.
- Regulatory Status: CJC-1295 is not an approved therapeutic, and development by the originator company was discontinued. It is now most commonly found as an unregulated research peptide labeled not for human use.
Notably, CJC-1295 with DAC is well-documented to raise GH and IGF-1, but evidence on specific clinical benefits, optimal dosing strategies, and long-term risks remains incomplete.
What Are The Storage Conditions For CJC-1295 – With DAC (10mg)?
- Shelf Life: Up to 24 months (when stored properly as a dry lyophilized peptide)
- Storage Temperature: Store at 2–8 °C for routine storage; for long-term storage, ≤ –20 °C is recommended.
- Transport: Room-temperature exposure during transport is generally acceptable for short periods.
- Protection: Keep protected from light and moisture in a tightly sealed vial.
If reconstituted for research use, typical guidance is to store at 2–8 °C and use within the product/lab’s validated stability window.
Are you looking to buy CJC-1295 – With DAC (10mg) online?
If you’re looking to order CJC-1295 – With DAC (10mg) online at wholesale prices, contact Medical Spa RX for guidance on how to do so.
This product is supplied strictly for laboratory research use only and is not approved for human or veterinary administration. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines. By purchasing or using this material, the buyer confirms that they are a qualified researcher and that the product will be used exclusively in controlled research settings compliant with all applicable regulations.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Ionescu M, Frohman LA. Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006